A new paradigm for the development of anticancer agents from natural products.
A novel pharmacology paradigm has been developed which quickly and efficiently moves prospective anticancer drugs from the discovery phase through pharmacology testing and into therapeutic trial assessment. Following discovery, the drug is first assessed in a clonogenic assay which determines the cytotoxic effect of different concentrations of the drug at 3 different exposure durations: 2h, 24h and continuous (168 h). Second, pharmacokinetic information is obtained in both plasma and tumor for the drug administered at the maximum tolerated dose given intravenously. The first study defines the time-concentration profile required to obtain a specific cell survival for the tumor cells; the second study determines the concentration-time profile that can be obtained in both plasma and tumor at the maximum tolerated dose of the drug. The integration of this information determines whether a successful therapeutic trial is possible. Only when a drug shows therapeutic efficacy is a proteomics-based mechanism of action study initiated. Two drugs have been assessed in this paradigm: salicortin and fascaplysin A.
Subramanian
Balanehru
B
Henry Ford Health System, Department of Internal Medicine, Division of Hematology and Oncology, Detroit, MI 48202, USA.
Nakeff
Alexander
A
Tenney
Karen
K
Crews
Phillip
P
Gunatilaka
Leslie
L
Valeriote
Fred
F
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D008962:Models, Theoretical; D009369:Neoplasms / Q000628:therapy; D010600:Pharmacology / Q000639:trends*; D040901:Proteomics
D000970:Antineoplastic Agents; D001688:Biological Products